Intec Pharma drug fails in Parkinson's trial

Intec Pharma announced its Parkinson's disease hopeful missed its primary endpoint in a phase 3 trial.

Accordion Pill (Carbidopa-Levodopa) failed to demonstrate superiority over Merck's Sinemet (Carbidopa-Levodopa) in terms of reduction in daily OFF time (where motor symptoms reappear) in the late stage trial.

The Israel-based drugmaker had hoped that extending the release of levodopa would reduce the time patients spend in off episodes, but the data on the drug candidate, called AP-CD/LD, did not deliver.

"While the data suggests that the AP CD/LD did achieve an acceptable safety profile and did treat Parkinson's disease symptoms, it did not achieve a statistically significant superiority to standard immediate release levodopa therapy," stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.

Read the press release.